Repros Therapeutics Inc.
2408 Timberloch Place
Suite B-7
The Woodlands
Texas
77380
United States
Tel: 281-719-3400
Fax: 281-719-3446
Website: http://www.reprosrx.com/
268 articles about Repros Therapeutics Inc.
-
Repros Announces Negative Opinion From the EMA for Enclomiphene
1/29/2018
The CHMP has formally issued a negative opinion for the centralized MAA for enclomiphene for the treatment of secondary hypogonadism previously submitted to the EMA by the Company's U.K. subsidiary, Renable Pharma. Limited.
-
Repros Receives Feedback Following an Oral Explanation With the EMA
12/18/2017
Repros today announced that following an Oral Explanation, it has received feedback that a negative opinion is likely to be received in January 2018 from the CHMP for the centralized MAA for enclomiphene for the treatment of secondary hypogonadism previously submitted to the EMA by the Company's U.K. subsidiary, Renable Pharma Limited.
-
The deal is expected to close in the first quarter of 2018.
-
Repros Therapeutics Reports Third Quarter 2017 Financial Results
11/13/2017
Net loss for the three month period ended September 30, 2017, was ($1.6) million or ($0.04) per share as compared to a net loss of ($4.2) million or ($0.17) per share for the same period in 2016.
-
Repros Therapeutics Reports Second Quarter 2017 Financial Results
8/14/2017
-
No Relief For Investors As The FDA Keeps Partial Hold On Repros Therapeutics's Proellex Program
7/17/2017
-
Repros Therapeutics Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
5/18/2017
-
Repros Therapeutics Announces Pricing Of $3 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock
5/18/2017
-
Repros Therapeutics Reports First Quarter 2017 Financial Results
5/10/2017
-
Repros Therapeutics Announces The Issuance Of New U.S. Patent Relating To Treatment Using Off Drug Intervals For Certain Uterine Conditions
4/17/2017
-
Repros Therapeutics Release: Company Holds Meeting With FDA To Discuss Oral Proellex In The Treatment Of Uterine Fibroids
4/10/2017
-
Repros Therapeutics Names Larry Dillaha, M.D., Its Permanent President And CEO
4/10/2017
-
Repros Therapeutics Reports Fourth Quarter And Year End 2016 Financial Results
3/31/2017
-
Repros Therapeutics Boss Steps Down, Interim CEO Named
2/2/2017
-
Repros Therapeutics Release: FDA Grants End Of Phase 2 Meeting To Discuss Phase 3 Requirements For Oral Proellex In The Treatment Of Uterine Fibroids
1/31/2017
-
Repros Therapeutics Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex In The Treatment Of Endometriosis
12/20/2016
-
Repros Therapeutics Requests Meeting With FDA To Discuss Phase III Requirements For Proellex In The Treatment Of Symptomatic Uterine Fibroids
12/13/2016
-
Repros Therapeutics Release: FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism
12/7/2016
-
Repros Therapeutics Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids
11/15/2016
-
Repros Therapeutics Reports Third Quarter 2016 Financial Results
11/9/2016